Acerux IV Infusion 250 mg/vial

Acerux IV Infusion is an antiviral medication containing Acyclovir (250 mg/vial) manufactured by Opsonin Pharma Ltd. Priced at ৳400 per vial, this intravenous formulation treats severe herpes infections. It inhibits viral DNA synthesis, particularly effective against Herpes simplex and Varicella-zoster viruses.

Clinically prescribed for immunocompromised patients with herpes simplex, shingles, or encephalitis, it requires slow IV administration over 1 hour. Dosage varies (5-10 mg/kg every 8 hours) based on infection type and immune status. Store at 15°C–25°C, protected from light/moisture.

Key indications include:

• Herpes encephalitis
• Severe genital herpes
• Shingles with systemic complications

Common side effects include nausea, renal impairment, and neurological symptoms. Drug interactions with probenecid/diuretics require monitoring. Pregnancy Category B status warrants cautious use. For overdose management, hemodialysis proves effective.

As an IV Infusion, Acerux ensures rapid systemic action. Opsonin Pharma maintains quality standards, making it a trusted choice among Bangladesh healthcare providers for managing resistant viral cases.

Adult dosing: 5 mg/kg every 8h for HSV/zoster, 10 mg/kg for encephalitis. Pediatric: 250-500 mg/m² BSA. Renal adjustment: CrCl 25-50 → q12h, CrCl <10 → q24h. Administer as 1-hour IV infusion. Treatment duration varies by infection severity (typically 7-14 days).

Some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. Local inflammatory reactions may occur if Acerux IV Infusion is inadvertently infused into extracellular tissues.

Pregnancy Category B. Use only if benefits outweigh risks. Excreted in breast milk – caution in lactation. Consider Acyclovir alternatives for non-life-threatening infections during pregnancy.

IV infusion ONLY – rapid administration causes nephrotoxicity. Hydrate with 500-1000ml fluid pre/post infusion. Monitor neurological status and renal function. Discontinue if CNS symptoms occur. Opsonin Pharma Ltd recommends strict aseptic technique during reconstitution.

Pediatrics: Dose by BSA (250-500 mg/m²). Geriatrics: Reduce dose due to decreased CrCl. Renal impairment: Extend dosing intervals per CrCl. Hepatic impairment: No specific adjustment needed.

Overdosage of intravenous Acerux has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with over dosage. Adequate hydration is essential to reduce the possibility of crystal formation in the urine. Hemodialysis significantly enhances the removal of Acerux from the blood and may, therefore, be considered an option in the management of overdose of Acerux.